Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers
This study has been completed.
Study NCT00039975 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: June 18, 2002 Last Updated: August 5, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Cardiovascular Diseases
Hypertension
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Vascular Diseases
Virus Diseases
Interventions listed in this trial
Indinavir sulfate
Ritonavir
Amlodipine
Diltiazem HCl
Additional drug interventions recognized in this trial
Calcium Channel Blockers
Diltiazem
HIV Protease Inhibitors
Indinavir
Protease Inhibitors
Verapamil
More general drug interventions related to this trial
Anti-Arrhythmia Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antihypertensive Agents
Antiviral Agents
Cardiovascular Agents
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Back to top of Main Content
